Updated Jul 16, 2026 · Last SEC filing 2026-06-12
Entrada Therapeutics, Inc. (TRDA) has filed 9 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-12. 3 Form 8-K material event filings were reported by TRDA in the last 90 days. 2 Form 144 notices of proposed sale were filed for TRDA stock. InsiderAlpha tracks every TRDA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001689375 |
|---|
| Form 4 filings (90d) | 9 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 2 |
| Latest Form 4 filing | 2026-06-12 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Zeiher Bernhardt G | Director | P — Open-market purchase | 5.0K | $5.86 | $29K | SEC | |
| Dowden Nathan J | President & COO | M — Option exercise | 15.0K | $1.74 | $26K | SEC | |
| Dowden Nathan J | President & COO | S — Open-market sale | 15.0K | $15.33 | $230K | SEC | |
| Sethuraman Natarajan | President, Research & Develop. | S — Open-market sale | 25.9K | $15.39 | $399K | SEC | |
| WENTWORTH KORY JAMES | Chief Financial Officer | S — Open-market sale [10b5-1] | 2.5K | $12.95 | $32K | SEC | |
| WENTWORTH KORY JAMES | Chief Financial Officer | S — Open-market sale [10b5-1] | 11.4K | $13.02 | $148K | SEC | |
| Dowden Nathan J | President & COO | S — Open-market sale [10b5-1] | 11.9K | $13.05 | $155K | SEC | |
| Dowden Nathan J | President & COO | S — Open-market sale [10b5-1] | 3.1K | $13.02 | $41K | SEC | |
| WENTWORTH KORY JAMES | Chief Financial Officer | S — Open-market sale [10b5-1] | 5.1K | $13.00 | $66K | SEC | |
| WENTWORTH KORY JAMES | Chief Financial Officer | S — Open-market sale [10b5-1] | 8.0K | $12.25 | $98K | SEC | |
| WENTWORTH KORY JAMES | Chief Financial Officer | F — Tax withholding / forfeiture | 5.7K | $11.76 | $67K | SEC | |
| Doshi Dipal | CEO | F — Tax withholding / forfeiture | 19.2K | $11.76 | $225K | SEC | |
| Sethuraman Natarajan | President, Research & Develop. | F — Tax withholding / forfeiture | 7.6K | $11.76 | $89K | SEC | |
| Dowden Nathan J | President & COO | F — Tax withholding / forfeiture | 14.0K | $11.76 | $165K | SEC | |
| Doshi Dipal | CEO | F — Tax withholding / forfeiture | 9.9K | $11.66 | $115K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Entrada Therapeutics, Inc. (TRDA). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Dowden Nathan J | 3 | $256K |
| Zeiher Bernhardt G | 2 | $29K |
| Sethuraman Natarajan | 1 | $399K |
| KIM PETER S | 1 | — |
| Radhakrishnan Maha | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in TRDA insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live TRDA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.